ABOUT US

Where clinical insight meets technological ambition

COMPANY

About Dova

Dova was born from a clear need: to overcome the outdated processes holding back GI care and research. Founded by Dr. Michael Byrne, and built by a team of clinicians, technologists, and innovators, we set out to harness AI to bring precision, speed, and scale to how GI diseases are detected, diagnosed, and monitored.

Our goal is simple—deliver smarter tools that improve care, expand access, and accelerate discovery

TEAM

At Dova, our team is our advantage

We’re a driven, multidisciplinary group focused ontransforming GI health through AI. We move fast, think deeply, and holdourselves to a high bar, not just in what we build, but how we work together.

We hire for character, curiosity, and conviction. People who care about doing meaningful work and doing it well. Because solving real problems takes more than skill—it takes trust, clarity, and shared ambition.

We are here to push boundaries, challenge assumptions, and make technology that truly matters.

Dr. Michael Byrne

FOUNDER, CHAIRMAN & CMO

Solveig Johannessen

CEO

Sunny Gurm

VP ENGINEERING

Adam Odeh

VP RA/QA

dj headshot

Daljinder (DJ) Sanghera

VP PRODUCT

caryn headshot

Caryn Hamm

FINANCIAL CONTROLLER

James Requa

SENIOR ML/AI ENGINEER

Ben Davies

SYSTEMS & QUALITY ENGINEERING MANAGER

Jiayu Zhang

SENIOR DATA ENGINEER

Chaucer Qiu

SENIOR DATA ENGINEER

Robert Mendel

SENIOR ENGINEER

Animesh Wandkar

QA SPECIALIST

James Core

GRANTS & INVESTOR RELATIONS ANALYST

SCIENTIFIC ADVISORY BOARD

Global clinical and scientific leadership at our core

Our global KOLs are recognized leaders across gastroenterology, AI, and clinical research, holding key roles in major societies, organizations, and institutions worldwide.

Dr Remo Panaccione

Professor of Medicine, Director of Inflammatory Bowel Disease Unit, Crohn’s Colitis Canada Endowed Research Chair in IBD, and Dean of MD Admissions at the University of Calgary 

Dr. Simon Travis

Professor of Clinical Gastroenterology, Senior Clinical Research Fellow, Kennedy Institute, University of Oxford; Past President of European Crohn’s and Colitis Organisation (ECCO) 

Dr. Kerri Novak

Clinical Associate Professor, IBD Group, University of Calgary; President-Elect of IBUS (International Bowel Ultrasound) group; Co-founder of iUSCAN (Intestinal Ultrasound Group of the United States and Canada)

Dr. Mike Dolinger

Assistant Professor, NYU Grossman School of Medicine, New York; Co-founder of iUSCAN (Intestinal Ultrasound Group of the United States and Canada) 

Dr. Vipul Jairath

Professor of Medicine and McDonald Endowed Chair in IBD Clinical Research, Western University, London, Ontario; Chief Medical Office at Alimentiv 

Dr. Brian Bressler

Director of IBD training, GI division head, Lead for IBD Centre of BC, St Paul’s Hospital, Vancouver 

Dr. Helmut Messman

Professor of Medicine, University of Augsburg; Past President of ESGE (European Society of Gastrointestinal Endoscopy)

Dr. James East

Professor of Medicine, Endoscopy Research Lead for the Translational Gastroenterology Unit, Clinical Lead for Endoscopy, John Radcliffe Hospital, University of Oxford 

Dr. Doug Rex

Distinguished Professor Emeritus, Indiana University Hospital, Indianapolis; Past President of ASGE (American Society of Gastrointestinal Endoscopy); Past President of ACG (American College of Gastroenterology); Past Chair of the US Multisociety Task Force on Colorectal Cancer

Dr. Bill Karnes

Clinical Professor of Medicine, Director of High Risk Program and Colonoscopy Program, University of California Irvine Medical Center

Dr. Nasim Parsa

Director of Digitial Health and Innovation, Co-director Esophageal Disorders Program, University of Minnesota

BOARD OF DIRECTORS

Experience that powers our mission

Dr. Michael Byrne is the founder and chairman of DOVA. He provides senior leadership and clinical expertise to DOVA and is a clinical innovator with over 20 years experience as a practicing physician. He is the founder of both DOVA and its former ai4gi joint venture. Dr. Byrne is a Clinical Professor of Medicine in the Division of Gastroenterology at Vancouver General Hospital and UBC, is the Director of the Interventional Endoscopy Fellowship at VGH, and is the former Director of Endoscopy at VGH/UBC. His main clinical interests are in the field of ERCP, interventional endoscopy, optical biopsy, colon cancer, pancreaticobiliary disease, and IBD.

Ford Nicholson is a Managing Principal and founder of Kepis & Pobe Financial Group which specializes in developing international energy and other natural resource assets. Over the past 25 years Ford has invested in and provided executive management to multiple international projects. Most recently, the firm has acted on behalf of various parties providing advisory services for the purposes of transacting in large scale assets in the South Atlantic basin. Mr. Nicholson is the former deputy chairman of the board of InterOil Corporation, a fully integrated company developing LNG for Asian markets formerly listed on the NYSE before its sale to ExxonMobil. He was a co-founder and Director of Nations Energy Ltd. in Kazakhstan and a co-founder and former board member of Bankers Petroleum Ltd. in Albania. Ford is also a former member of the President’s council of the International Crisis Group.

Most recently, Dr. Azam was the Head of the Cell & Gene Therapies Unit at Novartis Pharmaceuticals and was a member of the Pharmaceutical Executive Committee. He has an extensive US, Global and International pharmaceutical industry background, with strong experiences in science, clinical development, regulatory and commercial activities. While at Novartis, he lived and worked in the US and Switzerland. Previous roles at Novartis included Head of Global Medical Affairs & HEOR General Medicines, Chief Scientific Officer and Head of US Clinical Development & Medical Affairs and Global Head Regulatory Affairs for the Neurosciences & Ophthalmic Franchise. Prior to Novartis, he was the Chief Executive Officer of Novaccel Therapeutics LLC, a company he founded focusing on accelerating assets in the translational medicine setting. Prior to this he served as Chief Medical Officer at Aspreva Pharmaceutics Inc, a company that focused on orphan and rare autoimmune disease states. Aspreva was acquired by Galenica SA in 2008. Prior to this he worked at Johnson & Johnson in Pharmaceutical Research & Development and in Medical Devices at Johnson & Johnson Ethicon. He started his life sciences career with Warner Lambert-Parke Davis in 1998. Dr. Azam is a member of the Board of Directors of the Alliance for Regenerative Medicine. Dr. Azam is a graduate of the University of Liverpool, United Kingdom, where he completed undergraduate studies in Human Biology & Anatomy. He graduated from the University of Liverpool School of Medicine and attained board certification as an Obstetrician & Gynecologist in the UK.

With nearly 20 years of experience across health sciences technologies, education, life sciences, and aviation, Solveig Johannessen is known for leading business development, organizational transformation, and strategic growth. She has held leadership roles at Deloitte Digital, Molecular You, Roxar Emerson, and Heli-One, and founded Educe Design & Innovation, where she delivered over 40 projects for clients ranging from startups to Fortune 500 companies. Solveig holds an Executive MBA from Simon Fraser University and a Bachelor of Design from Emily Carr University.